Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models

Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models

Bibliographic Details
Main Authors:	Francesca Barone, Paul P Tak, Sean Lawler, James A Lederer, Marilin S Koch, Mykola Zdioruk, Michal O Nowicki, Alec M Griffith, Estuardo Aguilar, Laura K Aguilar, Brian W Guzik, E Antonio Chiocca
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/1/e003368.full

Similar Items

468 Enhancers and repressors of immunotherapy: translational perspectives on gene-mediated cytotoxic immunotherapy in glioblastoma
by: Sean Lawler, et al.
Published: (2020-11-01)

Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma
by: Marilin S. Koch, et al.
Published: (2022-09-01)

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
by: Marilin S. Koch, et al.
Published: (2020-11-01)

Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma
by: Lishu Chen, et al.
Published: (2022-03-01)

Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models
by: Marilin S. Koch, et al.
Published: (2023-05-01)

Oncolytic Virus Therapy Alters the Secretome of Targeted Glioblastoma Cells
by: Jakub Godlewski, et al.
Published: (2021-03-01)

Proteomic Analysis Implicates Vimentin in Glioblastoma Cell Migration
by: Michal O. Nowicki, et al.
Published: (2019-04-01)

Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy
by: Adrianne L. Jenner, et al.
Published: (2022-06-01)

1098 Oncolytic HSV blocking tumor-intrinsic PKR sensitizes glioblastoma to immunotherapy
by: Balveen Kaur, et al.
Published: (2023-11-01)

Oncolytic Virus Immunotherapy
by: Antonio Marchini, et al.
Published: (2021-07-01)

Immunotherapeutic Agents for Intratumoral Immunotherapy
by: Chih-Rong Shyr, et al.
Published: (2023-11-01)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
by: Jie Yin, et al.
Published: (2017-06-01)

Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
by: Aleksei A. Stepanenko, et al.
Published: (2018-12-01)

Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
by: Giulia Agliardi, et al.
Published: (2021-01-01)

Oncolytic Virus-Induced Autophagy in Glioblastoma
by: Margarita Kamynina, et al.
Published: (2021-07-01)

Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
by: Andrea R. Di Sebastiano, et al.
Published: (2018-05-01)

Measles Virus as an Oncolytic Immunotherapy
by: Christine E. Engeland, et al.
Published: (2021-02-01)

Oncolytic Adenovirus in Cancer Immunotherapy
by: Malin Peter, et al.
Published: (2020-11-01)

Fusogenic Viruses in Oncolytic Immunotherapy
by: Teresa Krabbe, et al.
Published: (2018-06-01)

Targeting Autophagy for Oncolytic Immunotherapy
by: Lulu Hu, et al.
Published: (2017-01-01)

Oncolytic viruses for cancer immunotherapy
by: Otto Hemminki, et al.
Published: (2020-06-01)

Characterization of intratumor microbiome in cancer immunotherapy
by: Zhao Zhang, et al.
Published: (2023-09-01)

395 Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma
by: Francesca Barone, et al.
Published: (2021-11-01)

Breaking Barriers: A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses
by: Alexandro Guterres, et al.
Published: (2024-01-01)

Modeling Oncolytic Viral Therapy, Immune Checkpoint Inhibition, and the Complex Dynamics of Innate and Adaptive Immunity in Glioblastoma Treatment
by: Kathleen M. Storey, et al.
Published: (2020-03-01)

Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
by: Xing Huang, et al.
Published: (2022-07-01)

Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword
by: Sarah E. Blitz, et al.
Published: (2022-02-01)

Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus
by: Eric Bartee, et al.
Published: (2023-06-01)

Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients
by: Sascha Marx, et al.
Published: (2022-11-01)

CELL TO CELL COMMUNICATION IN GLIOBLASTOMA PROGRESSION: INTRATUMORAL SYNAPSES?
by: María Losada-Pérez, et al.
Published: (2023-10-01)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
by: Christian Migliarese, et al.
Published: (2023-06-01)

Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy
by: Zhongbing Qi, et al.
Published: (2022-09-01)

Repurposing the yellow fever vaccine for intratumoral immunotherapy
by: Maria Angela Aznar, et al.
Published: (2020-01-01)

The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy
by: Sebastian Brito-Orama, et al.
Published: (2023-05-01)

Oncolytic vaccinia virus and cancer immunotherapy
by: Lihua Xu, et al.
Published: (2024-01-01)

Oncolytic herpes simplex virus and immunotherapy
by: Wenqing Ma, et al.
Published: (2018-12-01)

Updates on Oncolytic Virus Immunotherapy for Cancers
by: Cole Peters, et al.
Published: (2019-03-01)

Two roads for oncolytic immunotherapy development
by: Howard L. Kaufman, et al.
Published: (2019-02-01)

Perspectives on immunotherapy via oncolytic viruses
by: Alberto Reale, et al.
Published: (2019-02-01)

A Local and Abscopal Effect Observed with Liposomal Encapsulation of Intratumorally Injected Oncolytic Adenoviral Therapy
by: Tao Dong, et al.
Published: (2023-06-01)